Outlook Therapeutics Announces FDA Approval for First Ophthalmic Bevacizumab
Outlook Therapeutics received FDA approval for LYTENAVA (bevacizumab-vikg), the first ophthalmic formulation of bevacizumab, targeting a significant portion of the wet AMD market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day